A novel analgesic in a surgical model of osteoarthritis

Osteoarthritis is the most common form of joint disease affecting over 80% of the human

population above 75 years old and burdening health organizations worldwide. Osteoarthritis is

characterized by progressive joint degeneration resulting in chronic pain and loss of joint

function. Currently there is no cure for osteoarthritis; available treatments are only symptomatic

targeting pain and are associated with significant side effects, emphasizing the need for new

treatments.

Isovaline is a novel analgesic which showed remarkable effects in several pain models

without producing central nervous system side effects. The current study will examine the

analgesic profile of isovaIine in mice; we will assess the efficacy of isovaIine in alleviating the

signs of osteoarthritis and restoring the ability of the mice which underwent surgical

destabilization of the knee joint to exercise voluntarily. The effect of isovaline will be compared

to dicIofenac, and morphine the currently drugs of choice for osteoarthritic pain.

Faculty Supervisor:

Bernard Macleod

Student:

Partner:

TherExcell Pharma Inc

Discipline:

Life Sciences

Sector:

Manufacturing

University:

The University of British Columbia

Program:

Accelerate

Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Government

International

Load More

International

Load More